MarketCapExport financials
Bicycle Therapeutics plc (BCYC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Bicycle Therapeutics plc Balance Sheet 2025-2011 | BCYC
Brief overview of Bicycle Therapeutics plc's assets and capital
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Total assets increased by +49.6%, from $479.8 million to $717.6 million. A CAGR near 10.6% points to substantial expansion.
Growth in the asset base was not matched by liabilities: +49.6% versus -19.4%. The balance sheet moved in a more conservative direction.
Internal capital represents 85% of the balance sheet, previously 72.2%. This is a strong capital position.
The balance sheet holds more cash than interest-bearing debt; net debt is -$624.9 million, indicating minimal leverage.
The cash reserve occupies 87.5% of the balance sheet, previously 91.4%. It is one marker of short-term resilience.
Retained earnings are negative at -$899.8 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
Bicycle Therapeutics plc's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet Bicycle Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-625 M | -873 M | -491 M | -306 M | -406 M | -121 M | -90.2 M | -63.4 M | -67.7 M | - | - | - | - | - | - |
Long Term Debt |
669 K | 817 K | 30.7 M | 30.3 M | 29.9 M | 14.5 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.55 M | 5.33 M | 4.88 M | 3.12 M | 2.38 M | 844 K | 640 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
50.6 M | 96.6 M | 155 M | 86.5 M | 97.3 M | 42.6 M | 8.18 M | 143 M | 112 M | - | - | - | - | - | - |
Total Current Liabilities |
57 M | 67.2 M | 69.5 M | 53.3 M | 36.2 M | 23.1 M | 8.82 M | - | - | - | - | - | - | - | - |
Total Liabilities |
108 M | 164 M | 224 M | 140 M | 134 M | 65.7 M | 17 M | 151 M | 121 M | - | - | - | - | - | - |
Deferred Revenue |
2.96 M | 10.2 M | 25 M | 20.4 M | 19.3 M | 10.1 M | 728 K | 10 K | 3.98 M | - | - | - | - | - | - |
Retained Earnings |
-900 M | -681 M | -512 M | -331 M | -218 M | -152 M | -101 M | -69.9 M | -48.1 M | - | - | - | - | - | - |
Total Assets |
718 M | 957 M | 595 M | 411 M | 480 M | 161 M | 110 M | 81.6 M | 74 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
628 M | 880 M | 526 M | 339 M | 439 M | 136 M | - | 63.4 M | 67.7 M | - | - | - | - | - | - |
Book Value |
610 M | 793 M | 371 M | 271 M | 346 M | 95.5 M | 93.2 M | -69.8 M | -47.2 M | - | - | - | - | - | - |
Total Shareholders Equity |
610 M | 793 M | 371 M | 271 M | 346 M | 95.5 M | 93.2 M | -69.8 M | -47.2 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Bicycle Therapeutics plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
12.9 M | 13.7 M | 13.9 M | 14.1 M | 981 K | 1.76 M | 2.61 M | 3.99 M | 5.53 M | 6.73 M | 8.05 M | 9.38 M | 10.4 M | 11.9 M | 14.4 M | 10.9 M | 11 M | - | 14.1 M | 12.1 M | 2.5 M | 2.8 M | 3.02 M | 426 K | 645 K | 850 K | 1.06 M | 1.25 M | 1.42 M | 1.63 M | 1.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
17.4 M | 48.7 M | 49.2 M | 50.6 M | 76.2 M | 85.8 M | 85.9 M | 96.6 M | 109 M | 114 M | 142 M | 155 M | 153 M | 162 M | 133 M | 86.5 M | 86.1 M | - | 93.9 M | 97.3 M | 80.3 M | 60.7 M | 60.9 M | 42.6 M | 43.5 M | 30.6 M | 31.3 M | 8.18 M | 11.9 M | 12.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
61.9 M | 96.3 M | 98.1 M | 108 M | 145 M | 163 M | 144 M | 164 M | 166 M | 184 M | 191 M | 224 M | 223 M | 234 M | 186 M | 140 M | 128 M | - | 129 M | 134 M | 111 M | 84 M | 81.8 M | 65.7 M | 60.5 M | 47.6 M | 47.5 M | 17 M | 20.7 M | 21.7 M | 17 M | 29.3 M | 29.3 M | 29.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 2.88 M | 2.8 M | 2.96 M | 12.3 M | 14.6 M | 12.5 M | 10.2 M | 11.4 M | 11.6 M | 16.4 M | 25 M | 27.2 M | 29.8 M | 25 M | 20.4 M | 16.4 M | - | 19.2 M | 19.3 M | 17.5 M | 8.74 M | 10.1 M | 10.1 M | 7.19 M | 5.42 M | 6.05 M | 728 K | 808 K | 1.01 M | 728 K | 10 K | 10 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.02 B | -1.01 B | -961 M | -900 M | -880 M | -820 M | -742 M | -681 M | -629 M | -578 M | -538 M | -512 M | -463 M | -413 M | -370 M | -331 M | -301 M | - | -246 M | -218 M | -200 M | -186 M | -168 M | -152 M | -134 M | -124 M | -112 M | -101 M | -96.1 M | -86.7 M | -101 M | -69.9 M | -69.9 M | -69.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
567 M | 607 M | 652 M | 718 M | 764 M | 832 M | 884 M | 957 M | 997 M | 1.06 B | 547 M | 595 M | 639 M | 454 M | 429 M | 411 M | 417 M | - | 460 M | 480 M | 281 M | 226 M | 224 M | 161 M | 170 M | 119 M | 129 M | 110 M | 116 M | 126 M | 110 M | 81.6 M | 81.6 M | 81.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
470 M | 510 M | 560 M | 629 M | 649 M | 722 M | 794 M | 880 M | 891 M | 962 M | 458 M | 527 M | 573 M | 340 M | 294 M | 339 M | 361 M | 373 M | 407 M | 439 M | 260 M | 199 M | 196 M | 136 M | 150 M | 96.9 M | 110 M | 92.1 M | 96 M | 109 M | - | - | 63.4 M | 63.4 M | - | 67.7 M | - | - | - | 9.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
505 M | 510 M | 554 M | 610 M | 618 M | 669 M | 740 M | 793 M | 831 M | 874 M | 356 M | 371 M | 416 M | 220 M | 243 M | 271 M | 289 M | - | 330 M | 346 M | 171 M | 142 M | 142 M | 95.5 M | 110 M | 71 M | 81.8 M | 93.2 M | 95.3 M | 105 M | 93.2 M | 52.4 M | 52.4 M | 52.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
505 M | 510 M | 554 M | 610 M | 618 M | 669 M | 740 M | 793 M | 831 M | 874 M | 356 M | 371 M | 416 M | 220 M | 243 M | 271 M | 289 M | 311 M | 330 M | 346 M | 171 M | 142 M | 142 M | 95.5 M | 110 M | 71 M | 81.8 M | 93.2 M | 95.3 M | 105 M | 93.2 M | -69.8 M | -69.8 M | -69.8 M | -47.7 M | -47.2 M | - | - | - | -33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Bicycle Therapeutics plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
